
Opinion|Videos|September 18, 2024
Type 2 Inflammatory Diseases and Impact on Quality of Life
Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.
Advertisement
Episodes in this series

- How do type 2 inflammatory diseases, such as asthma, eosinophilic esophagitis, or chronic rhinosinusitis with nasal polyps, impact patients’ quality of life?
- What challenges do patients face in managing their type 2 inflammatory disease(s) on a daily basis?
- Describe type 2 inflammation. What diseases beyond those mentioned above can it be associated with?
- What causes this overactive inflammatory response? In your clinical practice, how often do you see patients with type 2 inflammation?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement



